Genus plc (LON:GNS - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 2,112.85 ($28.66) and traded as high as GBX 2,755 ($37.37). Genus shares last traded at GBX 2,615 ($35.47), with a volume of 70,297 shares.
Wall Street Analyst Weigh In
GNS has been the topic of a number of research reports. Shore Capital reiterated a "buy" rating and set a GBX 2,900 price target on shares of Genus in a research report on Thursday, September 4th. Deutsche Bank Aktiengesellschaft raised their target price on Genus from GBX 2,250 to GBX 2,550 and gave the company a "buy" rating in a research report on Tuesday, July 15th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, Genus has a consensus rating of "Buy" and a consensus target price of GBX 2,725.
Check Out Our Latest Report on Genus
Genus Trading Down 3.5%
The business has a 50 day simple moving average of GBX 2,511.45 and a 200-day simple moving average of GBX 2,112.85. The company has a debt-to-equity ratio of 53.12, a quick ratio of 1.08 and a current ratio of 1.80. The stock has a market capitalization of £1.72 billion, a P/E ratio of -42,177.42, a price-to-earnings-growth ratio of 2.87 and a beta of 0.37.
Genus (LON:GNS - Get Free Report) last issued its quarterly earnings results on Thursday, September 4th. The company reported GBX 81.80 earnings per share (EPS) for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, analysts predict that Genus plc will post 70.9644323 EPS for the current year.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.